AUPH
Aurinia Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.05B
P/E Ratio
7.38
EPS
$2.16
Beta
1.43
52W High
$16.88
52W Low
$7.29
50-Day MA
$15.74
200-Day MA
$14.48
Dividend Yield
—
Profit Margin
100.00%
Forward P/E
20.62
PEG Ratio
0.00
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is headquartered in Victoria, Canada.
Fundamentals
| Revenue (TTM) | $298.30M |
| Gross Profit (TTM) | $233.47M |
| EBITDA | $153.71M |
| Operating Margin | 53.30% |
| Return on Equity | 65.00% |
| Return on Assets | 13.70% |
| Revenue/Share (TTM) | $2.25 |
| Book Value | $4.34 |
| Price-to-Book | 3.59 |
| Price-to-Sales (TTM) | 6.87 |
| EV/Revenue | 5.79 |
| EV/EBITDA | 10.97 |
| Quarterly Earnings Growth (YoY) | 56.30% |
| Quarterly Revenue Growth (YoY) | 24.40% |
| Shares Outstanding | $128.60M |
| Float | $126.24M |
| % Insiders | 7.53% |
| % Institutions | 60.22% |
Historical Volatility
HV 10-Day
31.94%
HV 20-Day
31.96%
HV 30-Day
36.46%
HV 60-Day
36.28%
HV Rank
39.7%
Volatility is currently contracting
Analyst Ratings
Consensus ($17.00 target)
4
Buy3
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026